Aegerion’s Marketing of Juxtapid Draws Government Probe

Drug Industry Daily
A A
Government prosecutors are asking Aegerion Pharmaceuticals to hand over documents tied to sales and marketing of its cholesterol drug Juxtapid, putting the company in the spotlight for compliance concerns for a second time.

To View This Article:

Login

Subscribe To Drug Industry Daily